Therakos Institute Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

Our speaker meetings help healthcare professionals stay up-to-date with the latest scientific knowledge and advancements in clinical practice across all clinical applications. If you would like to receive more information, please contact your local sales representative.

Upcoming Meetings
Past Meetings

Sep 29 - 30, 2026

5th Advancing Immunomodulation Meeting

London, UK

Jun 18 - 19, 2026

6th Workshop on Solid Organ Transplantation - Potential roles of ECP in SOT

Monte Carlo, Monaco

Filter by:

Apr 17, 2026

ECP in GvHD: Evidence in clinical practice

Bari, Italy

Feb 27, 2026

Tailoring extracorporeal photopheresis for low body weight patients’ needs

Porto, Portugal

Nov 27, 2025

Therapeutic Synergy in GvHD: A Clinical Perspective

Leicester, United Kingdom

Nov 26, 2025

Therapeutic Synergy in GvHD: A Clinical Perspective

Sheffield, United Kingdom

Nov 6 - 7, 2025

Operator Days Rotherham

Rotherham, UK

Oct 27, 2025

Treating Sézary Syndrome patients in 2025

St Etienne Hospital, France

Sep 17 - 19, 2025

Operator Days Dublin. This event is in French

Dublin, Ireland

Jul 10, 2025

Pan London GvHD Meeting

London, United Kingdom

May 23, 2025

9th Nordic Photopheresis Meeting

Copenhagen, Denmark

May 22, 2025

Nordic Operators Day

Copenhagen, Denmark

Apr 17, 2025

Ruxolitinib and ECP combination in aGvHD and ECP for the treatment of lung cGvHD

Lyon, France

Mar 13 - 14, 2025

French Operator Days. This event is in French

Paris, France

Nov 14, 2024

Extracorporeal Photopheresis – Role in Chronic Lung Allograft Dysfunction and Pulmonary GvHD

Gothenburg, Sweden

Nov 13 - 15, 2024

Operator Days Dublin. This event is in German

Dublin, Ireland

Nov 6, 2024

The role of ECP in CTCL management

Valencia, Spain

Oct 4, 2024

Cutaneous T-Cell Lymphoma Management: An update

Riyadh, Saudi Arabia

Sep 4, 2024

Navigating the Challenges of Late Stage CTCL – Therapeutic Approaches and Patient-Centered Care

Dublin, Ireland

Jun 29, 2024

ECP Day in GvHD and CTCL

Abu Dhabi, United Arab Emirates

Feb 9, 2024

8th NORDIC PHOTOPHERESIS MEETING

Helsinki, Finland

Feb 8, 2024

NORDIC OPERATOR DAY: THERAKOS – THE HOME OF ECP

Helsinki, Finland

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Therakos Institute Speaker Meetings

Covering a broad range of topics related to scientific, regulatory, economic and technical aspects of ECP.

5th Advancing Immunomodulation Meeting

6th Workshop on Solid Organ Transplantation - Potential roles of ECP in SOT

ECP in GvHD: Evidence in clinical practice

Tailoring extracorporeal photopheresis for low body weight patients’ needs

Therapeutic Synergy in GvHD: A Clinical Perspective

Therapeutic Synergy in GvHD: A Clinical Perspective

Operator Days Rotherham

Treating Sézary Syndrome patients in 2025

Operator Days Dublin. This event is in French

Pan London GvHD Meeting

9th Nordic Photopheresis Meeting

Nordic Operators Day

Ruxolitinib and ECP combination in aGvHD and ECP for the treatment of lung cGvHD

French Operator Days. This event is in French

Extracorporeal Photopheresis – Role in Chronic Lung Allograft Dysfunction and Pulmonary GvHD

Operator Days Dublin. This event is in German

The role of ECP in CTCL management

Cutaneous T-Cell Lymphoma Management: An update

Navigating the Challenges of Late Stage CTCL – Therapeutic Approaches and Patient-Centered Care

ECP Day in GvHD and CTCL

8th NORDIC PHOTOPHERESIS MEETING

NORDIC OPERATOR DAY: THERAKOS – THE HOME OF ECP

Discover more

Courses

Webinars

Symposia

Ask the Expert

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS